NUVA Announces Licensing Agreements for 48 Generic Drugs for Canadian Markets
April 16 2014 - 12:48PM
Marketwired
NUVA Announces Licensing Agreements for 48 Generic Drugs for
Canadian Markets
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Apr 16, 2014) - NUVA
PHARMACEUTICALS INC. (the "Company" or "NUVA") (TSX-VENTURE:NPH)
(OTCQB:NUVPF) is pleased to announce that it has signed Cross
Referencing Agreements (the "CRAs") for prescription generic
products for Canadian markets. These agreements cover 48
prescription generic products and are for acute and chronic
diseases.
The company has signed CRAs with three large pharmaceutical
companies for multiple products in the prescription generic drug
lines. NUVA will market and sell these new product lines under its
own label.
NUVA is in the process of securing a Drug Establishment License
(the "DEL") from Health Canada. Upon receipt of the DEL, NUVA will
start filing for regulatory approval of these products with Health
Canada. NUVA will also initiate ordering, packaging and art work
related processes for these generic products. NUVA expects to build
its "NUVA" label Generic portfolio for the Canadian Market apart
from the "NUVA" range of Over-the-Counter products.
On behalf of:
NUVA PHARMACEUTICALS INC.
Jamie Lewin, Director and CFO
Cautionary Note Regarding Forward-looking Statements:
Information in this press release that involves NUVA's
expectations, plans, intentions or strategies regarding the future
are forward-looking statements that are not facts and involve a
number of risks and uncertainties. NUVA generally uses words such
as "outlook," "will," "could," "would," "might," "remains," "to
be," "plans," "believes," "may," "expects," "intends,"
"anticipates," "estimate," "future," "plan," "positioned,"
"potential," "project," "remain," "scheduled," "set to," "subject
to," "upcoming," and similar expressions to help identify
forward-looking statements. The forward-looking statements in this
release are based upon information available to NUVA as of the date
of this release, and NUVA assumes no obligation to update any such
forward-looking statements. Forward-looking statements believed to
be true when made may ultimately prove to be incorrect. These
statements are not guarantees of the future performance of NUVA and
are subject to risks, uncertainties and other factors, some of
which are beyond its control and may cause actual results to differ
materially from current expectations.
Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
NUVA Pharmaceuticals Inc.Jamie LewinDirector and
CFOjlewin@nuvapharm.com